Arrowhead Q1 net loss $173M; $825M Sarepta deal & plozasiran NDA accepted

ARROWHEAD PHARMACEUTICALS, INC.

2025-Q1 EPS reported -$1.39 revenue$2,500,000

Net loss of $173M ($1.39 diluted EPS), revenue $2.5M, operating loss $161.4M.
Sarepta collaboration: $825M upfront ($500M cash + $325M equity at $27.25/share, 35% premium), plus $250M over 5 years, up to $10B milestones.
Plozasiran NDA for familial chylomicronemia syndrome accepted; PDUFA date Nov 18, 2025.
Phase 3 PALISADE met primary endpoint; plozasiran reduced triglycerides up to 86% and acute pancreatitis.
Cash & investments $552.9M; company funded into 2028; obesity programs (ARO-INHBE, ARO-ALK7) entering Phase 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.